Ovid Therapeutics Inc . (NASDAQ:OVID), a pharmaceutical company currently trading at $0.65, has received a warning from the Nasdaq Stock Market LLC regarding its non-compliance with the minimum bid ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.

Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Oost NL, a regional development agency supporting innovation-driven companies, announced the pre-seed ...

Peptides act as signal mediators in the body and are on the rise as therapeutic agents. However, their full potential can ...

Neuropsychiatric disorders are becoming increasingly prevalent. Given their complex and multifactorial pathogenesis, there is an urgent need for ...

Genome-wide association studies (GWASs) have linked genetic variants to neuropsychiatric disorders, but their regulatory ...

The Global Implantable Drug Delivery Devices Market was valued at USD 26.7 Bn in 2023. It is expected to reach USD 57.1 Bn by 2033, with a CAGR of 8.1% ...

Profiling cells from ovarian endometriosis revealed signaling interactions that may sustain legion growth, highlighting ...